Monotherapy of PD-1 Inhibitor Camrelizumab Reverses Advanced Lung Squamous Cell Carcinoma with Low PD-1 Expression: A Case Report.

ABSTRACT:

Introduction

Chemotherapy plus immunotherapy is the standard treatment worldwide for advanced lung squamous cell carcinoma with high programmed cell death protein-1 (PD-1) expression. The use of immunotherapy alone against advanced lung squamous cell carcinoma is rarely reported, and data on PD-1 inhibitor camrelizumab are missing. We report the first case of camrelizumab monotherapy, which can be a reference for the clinical applications of camrelizumab in a wider context.

Case presentation

We herein present a 69-year-old male case of advanced squamous cell carcinoma with low PD-1 expression, in which camrelizumab monotherapy was administered every 3 weeks. Camrelizumab monotherapy reversed advanced lung squamous cell carcinoma without recurrence or obvious side effects dur

SUBMITTER: Zheng X 

PROVIDER: S-EPMC11521453 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature